Last reviewed · How we verify
A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
Details
| Lead sponsor | Astellas Pharma Inc |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | 2007-11 |
| Completion | 2010-07 |
Conditions
- Advanced Solid Tumors
Interventions
- OSI-930 and erlotinib
Primary outcomes
- Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles — 18 months
Countries
United States, United Kingdom